These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 17179659)

  • 1. The ABCs (Antibody, B cells, and Carbohydrate epitopes) of cholera immunity: considerations for an improved vaccine.
    Provenzano D; Kovác P; Wade WF
    Microbiol Immunol; 2006; 50(12):899-927. PubMed ID: 17179659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-Cell Analysis of the Plasmablast Response to Vibrio cholerae Demonstrates Expansion of Cross-Reactive Memory B Cells.
    Kauffman RC; Bhuiyan TR; Nakajima R; Mayo-Smith LM; Rashu R; Hoq MR; Chowdhury F; Khan AI; Rahman A; Bhaumik SK; Harris L; O'Neal JT; Trost JF; Alam NH; Jasinskas A; Dotsey E; Kelly M; Charles RC; Xu P; Kováč P; Calderwood SB; Ryan ET; Felgner PL; Qadri F; Wrammert J; Harris JB
    mBio; 2016 Dec; 7(6):. PubMed ID: 27999163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A one dose experimental cholera vaccine.
    Muse M; Grandjean C; Wade TK; Wade WF
    FEMS Immunol Med Microbiol; 2012 Oct; 66(1):98-115. PubMed ID: 22612159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acid-detoxified Inaba lipopolysaccharide (pmLPS) is a superior cholera conjugate vaccine immunogen than hydrazine-detoxified lipopolysaccharide and induces vibriocidal and protective antibodies.
    Grandjean C; Wade TK; Ropartz D; Ernst L; Wade WF
    Pathog Dis; 2013 Mar; 67(2):136-58. PubMed ID: 23620159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunisation against cholera with a Ty21a-cholera hybrid.
    La Brooy JT; Forrest B; Bartholomeusz C
    Ann Sclavo Collana Monogr; 1986; 3(1-2):143-7. PubMed ID: 3426872
    [No Abstract]   [Full Text] [Related]  

  • 6. Sublingual Adjuvant Delivery by a Live Attenuated Vibrio cholerae-Based Antigen Presentation Platform.
    Liao J; Gibson JA; Pickering BS; Watnick PI
    mSphere; 2018 Jun; 3(3):. PubMed ID: 29875145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of lipopolysaccharide-mimicking peptides and their immunoprotectivity against Vibrio cholerae serogroup O1.
    Mohammad Pour Ghazi F; Gargari SL
    J Pept Sci; 2016 Nov; 22(11-12):682-688. PubMed ID: 27766741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired immune response to natural infection as a correlate of vaccine failure in a field trial of killed oral cholera vaccines.
    Clemens J; Rao M; Sack D; Ahmed F; Khan MR; Chakraborty J; Kay B; Huda S; Yunus M; van Loon F
    Am J Epidemiol; 1995 Oct; 142(7):759-64. PubMed ID: 7572947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral vaccine against cholera prepared from Vibrio cholerae antigen(s).
    Chaicumpa W; Chaisri U; Tapchaisri P; Chongsa-Nguan M; Pongponratn E
    Southeast Asian J Trop Med Public Health; 1987 Jun; 18(2):142-8. PubMed ID: 3313733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B-cell responses to lipopolysaccharide epitopes: Who sees what first - does it matter?
    Wade WF
    Am J Reprod Immunol; 2006; 56(5-6):329-36. PubMed ID: 17076677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit-whole cell vaccine.
    Svennerholm AM; Jertborn M; Gothefors L; Karim AM; Sack DA; Holmgren J
    J Infect Dis; 1984 Jun; 149(6):884-93. PubMed ID: 6736680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic significance of the nonlipopolysaccharide antigens of Vibrio cholerae.
    Attridge SR; Rowley D
    J Infect Dis; 1983 Nov; 148(5):931-9. PubMed ID: 6195273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploiting cholera vaccines as a versatile antigen delivery platform.
    Silva AJ; Eko FO; Benitez JA
    Biotechnol Lett; 2008 Apr; 30(4):571-9. PubMed ID: 18008168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipopolysaccharide modifications of a cholera vaccine candidate based on outer membrane vesicles reduce endotoxicity and reveal the major protective antigen.
    Leitner DR; Feichter S; Schild-Prüfert K; Rechberger GN; Reidl J; Schild S
    Infect Immun; 2013 Jul; 81(7):2379-93. PubMed ID: 23630951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigen-specific immunoglobulin A antibodies secreted from circulating B cells are an effective marker for recent local immune responses in patients with cholera: comparison to antibody-secreting cell responses and other immunological markers.
    Qadri F; Ryan ET; Faruque AS; Ahmed F; Khan AI; Islam MM; Akramuzzaman SM; Sack DA; Calderwood SB
    Infect Immun; 2003 Aug; 71(8):4808-14. PubMed ID: 12874365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers.
    García L; Jidy MD; García H; Rodríguez BL; Fernández R; Año G; Cedré B; Valmaseda T; Suzarte E; Ramírez M; Pino Y; Campos J; Menéndez J; Valera R; González D; González I; Pérez O; Serrano T; Lastre M; Miralles F; Del Campo J; Maestre JL; Pérez JL; Talavera A; Pérez A; Marrero K; Ledón T; Fando R
    Infect Immun; 2005 May; 73(5):3018-24. PubMed ID: 15845509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A single-dose antihelminthic treatment does not influence immunogenicity of a meningococcal and a cholera vaccine in Gabonese school children.
    Brückner S; Agnandji ST; Elias J; Berberich S; Bache E; Fernandes J; Loembe MM; Hass J; Lell B; Mordmüller B; Adegnika AA; Kremsner P; Esen M
    Vaccine; 2016 Oct; 34(44):5384-5390. PubMed ID: 27642131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experimental studies on cholera immunization. 4. The antibody response to formalinized Vibrio cholerae and purified endotoxin with special reference to protective capacity.
    Svennerholm AM
    Int Arch Allergy Appl Immunol; 1975; 49(4):434-52. PubMed ID: 808500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preparation and evaluation of a freeze-dried oral killed cholera vaccine formulation.
    Borde A; Larsson A; Holmgren J; Nygren E
    Eur J Pharm Biopharm; 2011 Nov; 79(3):508-18. PubMed ID: 21757004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunity Provided by an Outer Membrane Vesicle Cholera Vaccine Is Due to O-Antigen-Specific Antibodies Inhibiting Bacterial Motility.
    Wang Z; Lazinski DW; Camilli A
    Infect Immun; 2017 Jan; 85(1):. PubMed ID: 27795359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.